Change management
From Pilot to Practice: Change Management for Copilot in Pharma
Your Copilot Rollout Was a Success. But Has That Success Quietly Become Your Ceiling?
CLIMB is our consulting-led change management methodology, purpose-built for pharma organisations running Microsoft Copilot at scale.
It doesn’t ask “is anyone using Copilot?” That question has already been answered. It answers a harder, more valuable one: how deeply is your organisation actually using it, and what’s the fastest way to close the distance to where it needs to be?
Most pharma Copilot rollouts aren’t failing. They’re succeeding, but at the wrong altitude: a small pocket of innovators pulling far ahead, a large, capable majority sitting just below its tipping point, and a bridge between them that isn’t yet strong enough to carry the whole organisation across.
CLIMB closes that gap, built specifically around the compliance and scientific rigour that Life Sciences teams operate within every day.
Turn Proven Expertise Into the Default Choice, Not Just an Option: Move what your best users have already proven works out of a crowded library and into the validated path everyone finds first.
Close Whichever Gap Matters Most to You: Whether that’s activating your 1s or elevating your capable 5s to genuine mastery, and for most organisations, it’s a deliberate mix of both.
Build a Culture, Not a Training Event: Establish the champion networks and shared practices that keep advancing long after the rollout ends.
You Don't Have An AI Adoption Problem
You most likely have a maturity distribution problem. Your organisation has already invested heavily in Microsoft Copilot. And unlike many industries still stuck at the starting line, pharma teams are genuinely using it, productively, for real work. Medical Information teams are drafting literature summaries. MSLs are prepping for calls faster. Insight teams are cutting through congress transcripts instead of drowning in them.
The problem is where the ceiling sits. Think of Copilot maturity on a scale from 1 to 10.
The 10s are your innovators – a small, not always visible cohort building custom agents, chaining workflows together, extracting genuinely differentiated value. They’re rare, and they usually operate with no formal mandate and no clear route to scale what they’ve built.
The 5s are your majority. They’re not beginners – they’re competent, confident, everyday users getting real value from Copilot. But they’re using it exactly as it comes out of the box: one prompt, one task at a time. They haven’t plateaued for lack of skill, or even for lack of training, most pharma organisations already run solid Copilot training programmes. They’ve plateaued because they haven’t yet crossed the specific threshold where Copilot’s value starts dramatically multiplying. It’s not unlike a neuron approaching its ‘action potential’: most of the necessary charge is already there, and it takes only a few more of the right inputs, structured data, the right agent, the right workflow, before the whole system fires with real force. Most of your 5s are sitting just below that tipping point, closer to it than they realise.
The 1s are a smaller group who’ve barely engaged, usually not from resistance, but because Copilot hasn’t yet been connected to something that matters directly in their workflow.
The first is activation: helping your 1s cross into confident, everyday use to become 5s.
The second is elevation: helping your 5s climb past their tipping point into genuine mastery, the 10s.
This creates two distinct opportunities, and they’re genuinely different propositions, with different resourcing needs and different value profiles.
The Data Confirms It: A Hierarchy Of Maturity, Not Just Usage
Our independent research of 2,500 employees across large enterprises maps precisely onto this pattern, and it plays out inside pharma organisations implementing Copilot every day.*
High Adoption, Shallow Depth: 61.3% of employees are using AI in some form – genuinely, not superficially. But usage frequency remains low, the signature of a “5”: actively engaged, but not yet over the threshold into transformative use.
A Confidence-Versus-Capability Gap: 68% of employees claim a good understanding of AI, yet only 46.5% say their organisation provides adequate training to move beyond that baseline. People know enough to be productive. Many are just short of the input that would make them transformative.
A Widening Seniority Divide in Depth of Use: C-level executives report AI usage of 89.7%; entry-level sits at 37%. This isn’t purely a competence gap, it’s an exposure gap, and it maps onto both opportunities at once. The 37% entry-level figure represents real, near-term activation potential (the 1-to-5 climb), while everyday users already sitting comfortably at “5” represent the larger elevation opportunity still ahead of them.
A Confidence Ceiling: 41.3% of employees are unconvinced of their ability to integrate AI further into their workflow, not because the tool doesn’t work for them, but because the specific next step that would tip them over hasn’t yet been made obvious.
This is the pattern behind every Copilot rollout we see in pharma: a handful of 10s quietly pulling ahead, a large and capable population of 5s sitting just below their tipping point, and a smaller group of 1s still waiting for the moment that activates them.
There’s a well-documented reason this keeps happening (organisational theorists have mapped this exact dynamic before, from Rogers’ classic diffusion curve to Geoffrey Moore’s idea of the “chasm” separating early enthusiasts from the mainstream). Most technology rollouts stall at exactly this point: the chasm between the early few who love a new tool and the larger group who need to be shown, not sold.
CLIMB exists to build a stronger bridge across that chasm, whichever side of it matters most to your organisation right now.
The Pharma-Specific Version Has Sharper Edges
Shared Agent Libraries Solve Duplication, But Not Discovery: Many pharma organisations have sensibly built shared agent libraries, so a good build in one country isn’t reinvented in another. But a new problem emerges: when a library holds thirty congress-abstract agents, which is actually best? Are your 5s equipped to compare them before even starting their real task, or does the volume just create overwhelm? An uncurated library can function less like a toolkit and more like an app-store-overload problem, quietly pushing people back to the one prompt they already trust.
Your 5s Are Leaving Real Value on the Table: Most Medical Affairs and Commercial teams are using Copilot well within its intended lane. That’s great, but it’s a fraction of what’s possible once inputs are properly structured, outputs are standardised, and agents are purpose-built for pharma’s specific scientific and regulatory context, the difference between working near the threshold and actually crossing it.
Commoditised Intelligence Means Zero Competitive Edge: If every pharma company’s 5s use the same out-of-the-box Copilot the same way, everyone gets the same generic output. Your investment becomes indistinguishable from your competitors’ unless you deliberately close the gap between your average user and your best one.
Scale Creates Its Own Assurance Challenge: The more successful, and more numerous, your innovators’ agents become, the more validation and oversight work needs to keep pace too, otherwise the rate of building starts to outstrip the rate of confirming what’s actually safe to use widely.
This is not a failure of your people, or of the shared libraries many pharma organisations have already built. Your 10s are proof the technology works. Your 5s are proof it’s already delivering value. What’s usually still missing is the next layer: a structure that curates the best of what your 10s have built, validates it, and actively guides your 5s toward it, rather than simply making it available and hoping the right people find it.
There’s a deeper cost hiding in this gap, too. Every hour a Medical Lead or MSL spends hunting through a crowded agent library for the right tool, or quietly reverse-engineering a better prompt from scratch, is an hour not spent on the work only they can do: advancing patient outcomes. Closing the maturity gap isn’t just an efficiency play. It’s about freeing your best talent to spend their time being who they want to be, not amateur AI engineers.
The Climb Methodology
Consulting-led, tool-enabled change management
We don’t believe this is solved with a training deck and a launch email. Neither is it a technology problem you can buy your way out of. It’s both, done properly, together, in service of two connected goals: helping your 1s cross into confident use, and helping your 5s climb past their tipping point to genuine mastery.
C
C - CHART: Map Your Organisation Across the Maturity Curve
Before we recommend anything, we assess, not just “who’s using Copilot,” but how and how deeply. We audit your existing tenant to surface what your 10s have already built. We run structured workshops across teams and seniority levels to understand exactly where your 5s sit relative to their tipping point, and how many of your 1s are genuinely just one step from activation.
This gives you, for the first time, a clear picture: who your innovators are, how large your capable-but-plateaued majority is, and exactly what each group needs to move forward.
L
L - LEARN: Build the Bridge to the Next Threshold
• A tiered AI education strategy spanning both climbs: foundational activation paths for your 1s, and role-specific advancement paths that show your 5s precisely what a 10 does differently.
• Clear AI trust and assurance frameworks, so scaling capability doesn’t mean scaling risk.
• AI champions at middle management level, identifying your existing 10s and giving them a formal mandate to mentor, rather than leaving them to build in isolation.
• A cross-hierarchical AI steering group, ensuring the path forward reflects operational reality, not just leadership ambition.
I
I - INSTITUTIONALISE: Turn a Crowded Library Into a Curated Standard
This is where consulting meets practical tooling. Rather than leaving your 5s to wade through dozens of similar, unranked agents, we help you create a validated, curated, gold-standard path, built once by your best people, and positioned as the default answer, not just one more option among many.
(This is precisely the thinking behind our Copilot AIM Platform, for medical insights management, which sits natively inside the Microsoft ecosystem you already own. Link to read more about AIM)
Why ask every team to keep rediscovering the same fixes your 10s have already found, or sift through a growing pile of near-identical agents to find them?
M
M - MENTOR: Because Getting to 10 Isn't a One-Off "Training Event"
The organisations that climb this curve fastest aren’t the ones with the best technology, they’re the ones that build genuine communities of practice around it. Spaces where your 10s show your 5s not just which agents to use, but how to ask better questions, where Copilot’s limits are, and how to structure outputs so they actually get consumed and acted on.
We help build that: champion networks, shared prompt and agent libraries, regular showcases of what’s working – an ongoing practice, not a one-off rollout.
B
B - BENCHMARK: Prove the Shift, Then Multiply It
We track the metrics that matter: how many of your 1s have crossed into active use, how many of your 5s are genuinely climbing past their tipping point, how much time is being reclaimed, and where risk is dropping. We use these wins to build the case for the next phase, because closing this gap once, in one team, is proof of concept. Closing it everywhere is the transformation.
Why LSP @ WPP Enterprise Solutions
The specialist Life Sciences practice is not a pure-play Microsoft integrator bolting on generic AI services, nor a pharma strategy consultancy without deep technical depth. We sit precisely at the intersection pharma organisations need: over a decade of Medical Affairs and commercial expertise, native Microsoft partnership credentials, and genuine change management capability, the part of this challenge most partners simply aren’t resourced to solve properly.
Every month your 10s’ best work stays buried in a crowded library, and your 5s stay capable but capped just below their tipping point, the value gap between what you’re paying for and what you’re getting keeps widening.
The Choice
Without CLIMB: Your innovators’ best work stays buried in a crowded library. Your majority stays productive but just short of its tipping point. Your disengaged users remain one small nudge away from activation, indefinitely. Your Copilot investment quietly becomes a commodity, the same tool, used the same modest way, as every competitor.
With CLIMB: Your best thinking, captured, curated, and actively surfaced to the people who need it. Both your disengaged users and your plateaued majority moving deliberately toward mastery. A genuine community of practice that keeps advancing. A measurable, organisation-wide shift from good to exceptional. And a Copilot investment that finally becomes what it was always meant to be: your competitive edge, not your shared baseline.